Better progression-free survival, as well as improved responses, were seen when lenvatinib was combined with either pembrolizumab or everolimus versus standard-of-care sunitinib in the treatment of patients with advanced renal cell carcinoma receiving therapy in the frontline setting.
Statistically significant improvements in median progression-free survival were observed in patients with HER2- amplified disease who were treated with pembrolizumab in combination with trastuzumab and cisplatin plus capecitabine compared with those without HER2-amplified disease.
Following a fixed-treatment duration of ibrutinib combined with venetoclax achieved similar 1-year disease-free survival in patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma.
When compared to currently approved therapies, KTE-X19 demonstrated comparable pharmacologic and clinical outcomes in patients with high-risk MCL characteristics versus lower-risk characteristics defined by tumor protein TP53 mutation or high Ki-67 proliferation index.
Disease progression and treatment with hydroxychloroquine and azithromycin were associated with increased all-cause 30-day mortality in patients with cancer compared to patients either in remission or with no evidence of disease, according to data presented during a 2020 ASCO Virtual Scientific Program press briefing.